The FDA-cleared device failed its main test in the largest trial yet
STUDY: Loo SK et al, Research Square
STUDY TYPE: Randomized controlled trial
FUNDING: National Institute of Mental Health
Background
The FDA cleared the Monarch trigeminal nerve stimulation (TNS) device for ADHD in children aged 7 to 12 in 2019. The device stimulates the trigeminal nerve overnight with mild electrical current. A small trial supported it, but a larger one did not. Now, a new large trial brings mixed results.
The Study
- 219 medication-free children with moderate to severe ADHD were randomized; 211 completed.
- Children used active stimulation (120 Hz) or a low-frequency control (2 Hz) nightly for 4 weeks.
- Primary outcome = clinician-rated ADHD scale (ADHD-RS); Secondary = Clinical Global Impression of Improvement (CGI-I).

The Monarch System
Results
There was no significant difference on the primary outcome, the one that counts: 26% drop in symptoms with treatment vs 22% with placebo). Parent ratings (SNAP-IV) also showed no difference.
The CGI-I, however, showed improvement: 35% of the active group were much improved or better, versus 15% of controls (odds ratio 3.07; number needed to treat 5).
The inconsistency is puzzling. With twice as many responders, each improving by about half, we’d expect symptom scores to separate too.

Side Effects
None.
Limitations
- Preprint, not yet peer reviewed
- The primary outcome failed
- The claim that the 2-Hz control is partly active is post hoc (data fishing), and its 15% response rate matched an inert sham in the earlier trial
- Only 4 weeks long
Practice Implications
- TNS failed in its two large trials, but remains FDA cleared, which is a lower bar to pass than approval.
- That said, the approval bar has lowered a lot in the past two years.
—Chris Aiken, MD
Director, Psych Partners
Editor in Chief, Carlat Psychiatry Report







